オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1 mg (equivalent: pramipexole, qty 0.7 mg) - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; microcrystalline cellulose - ? treatment of signs and symptoms of idiopathic parkinson?s disease. it may be used as monotherapy or in combination with levodopa ? the symptomatic treatment of primary restless legs syndrome.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1 mg (equivalent: pramipexole, qty 0.7 mg) - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; microcrystalline cellulose - treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1 mg - tablet - excipient ingredients: pregelatinised maize starch; mannitol; microcrystalline cellulose; povidone; purified talc; magnesium stearate - the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. the symptomatic treatment of primary restless legs syndrome.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1.5 mg - tablet - excipient ingredients: pregelatinised maize starch; mannitol; microcrystalline cellulose; povidone; purified talc; magnesium stearate - the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.5 mg - tablet - excipient ingredients: pregelatinised maize starch; mannitol; microcrystalline cellulose; povidone; purified talc; magnesium stearate - the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

ベルギー - ドイツ語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mylan - pramipexole dihydrochloride monohydrate - tablette - 1,1 mg - pramipexole dihydrochloride monohydrate - pramipexole

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - pramipexole dihydrochloride monohydrate -

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - pramipexole dihydrochloride monohydrate -

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.125 mg - tablet, uncoated - excipient ingredients: povidone; maize starch; mannitol; colloidal anhydrous silica; magnesium stearate - sifrol is indicated for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. sifrol is indicated for the symptomatic treatment of primary restless legs syndrome.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.25 mg - tablet, uncoated - excipient ingredients: magnesium stearate; mannitol; maize starch; povidone; colloidal anhydrous silica - sifrol is indicated for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. sifrol is indicated for the symptomatic treatment of primary restless legs syndrome.